REFINING PHARMA
Forbes Middle East - English|April 2022
Said Darwazah, Executive Chairman of Hikma Pharmaceuticals, has helped build his family business into a global enterprise over the last 41 years. With a market cap of over $6.2 billion, the Jordanian company is today competing with international heavyweights.
JASON LASRADO
REFINING PHARMA

While the last two years have seen a number of international pharma companies, such as Pfizer and AstraZeneca, become household names thanks to vaccine rollouts, the Middle East's biggest pharmaceutical company has flown largely under the radar.

Yet Hikma, which was founded in Jordan, is a formidable global player. “We actually have 17% market share in the U.S., in the hospitals," says Said Darwazah, Executive Chairman of Hikma Pharmaceuticals. “That means one out of every six products that's used in the hospitals in the states is a Hikma product."

Hikma has made its mark developing, manufacturing, and marketing branded and non-branded generic medicines across the Middle East, Europe, the U.S., and Asia Pacific. Established in 1978, today the FTSE 100 company has a market cap of over $6.2 billion, 31 manufacturing plants, and seven R&D centers worldwide. Its share price has increased over seven times since it went public in 2005. In 2021, Hikma recorded revenues of $2.6 billion-9% higher than 2020. And while 2021 profits were down 2% compared to 2020 and are still 13.6% lower than pre-pandemic levels, in February 2022, the company announced that it would be executing a share buyback program of up to $300 million during 2022, and in March Fitch reaffirmed its BBB- rating.

The drug-maker manufactures or sells over 670 products globally, with the U.S. being its biggest market, contributing 60% to total revenues, followed by MENA, with Saudi and Egypt being the biggest markets in the region. Injectables are by far the company's biggest source of revenue, generating $1.1 billion in 2021, compared to $820 million from non-injectables and $669 million from its branded drug business.

Esta historia es de la edición April 2022 de Forbes Middle East - English.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

Esta historia es de la edición April 2022 de Forbes Middle East - English.

Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.

MÁS HISTORIAS DE FORBES MIDDLE EAST - ENGLISHVer todo
Celebrating Emirati Businesswomen and Entrepreneurs on Emirati Women's Day
Forbes Middle East - English

Celebrating Emirati Businesswomen and Entrepreneurs on Emirati Women's Day

As part of the U.A.E.’s annual Emirati Women’s Day celebrations, the Abu Dhabi Business Women Council and the Abu Dhabi Chamber hosted an event on August 28, 2024, under the theme “We Collaborate for Tomorrow,” celebrating the role and achievements of Emirati women.

time-read
2 minutos  |
Sep 2024
THE MIDDLE EAST'S TOP 100 HEALTHCARE LEADERS 2024
Forbes Middle East - English

THE MIDDLE EAST'S TOP 100 HEALTHCARE LEADERS 2024

MENA’s healthcare landscape is evolving towards integration, marked by the rise of fully comprehensive ecosystems. Industry giants are setting future trends, driven by systems that thrive on data abundance, accessibility, and intersectoral collaboration.

time-read
6 minutos  |
Sep 2024
SCOUTING FOR OPPORTUNITIES
Forbes Middle East - English

SCOUTING FOR OPPORTUNITIES

Ayman Cheikh-Lahlou, Chairman and CEO of the Morocco-based Cooper Pharma, took the helm of the family-owned pharmaceutical company in 2005 and has seen business boom over nearly 20 years. Now, he’s exploring expansion opportunities in new markets.

time-read
7 minutos  |
Sep 2024
TURNING THE TIDE
Forbes Middle East - English

TURNING THE TIDE

Irina Zaporozhets, President and General Manager for Eli Lilly Suisse S.A. in the META region is driving expansion, focusing on innovation and patient-centric care. As she navigates regional challenges, her commitment to expanding access to medicine remains at the forefront.

time-read
7 minutos  |
Sep 2024
Supercharging AI
Forbes Middle East - English

Supercharging AI

Armed with a newly raised 640 million, GROQ thinks it can challenge one of the world’s most valuable companies with a purpose-built chip designed for Al from scratch.

time-read
5 minutos  |
Sep 2024
How Technology is Accelerating Digital Equality in Diverse Markets
Forbes Middle East - English

How Technology is Accelerating Digital Equality in Diverse Markets

The rise of smartphones and digital technologies has transformed our daily lives, contributing to the evolution of connected consumers.

time-read
2 minutos  |
Sep 2024
Rare Fortune
Forbes Middle East - English

Rare Fortune

Money manager JAMES LITINSKY turned a bad junk bond bet into a $400 million fortune. His MP Materials operates a strategic mine and will begin manufacturing supermagnets for electric vehicles next year.

time-read
6 minutos  |
Sep 2024
The State of Mental Health in the Middle East
Forbes Middle East - English

The State of Mental Health in the Middle East

While mental health awareness is on the rise, the Middle East faces some challenges in providing care. Still, we're seeing some progress.

time-read
2 minutos  |
Sep 2024
Big Breakthroughs
Forbes Middle East - English

Big Breakthroughs

From gene therapy to nasal sprays, these were some of the most significant healthcare breakthroughs in the last year.

time-read
3 minutos  |
Sep 2024
MENA's 5 Most Valuable Healthcare Companies 2024
Forbes Middle East - English

MENA's 5 Most Valuable Healthcare Companies 2024

The combined market cap of 57 healthcare companies listed on MENA's stock exchanges hit $83.7 billion on August 13, 2024, with the top five companies accounting for about 62.4% of the total market cap. These are MENA's five most valuable healthcare companies in 2024.

time-read
2 minutos  |
Sep 2024